https://www.zenithepigenetics.com/about/management

He is now listed in the mangement section of the website

Edward van der Horst is the Vice President of Discovery Research and Preclinical Development. He has worked with small molecules, antibodies, and antibody-drug conjugates during his 16 years in the biotechnology industry and has extensive experience in target discovery, selection and validation in the oncology and immuno-oncology space.

Prior to joining Zenith, Edward spearheaded the preclinical drug development efforts at Igenica Biopharmaceuticals Inc. which resulted in the successful acquisition of immuno-oncology assets by Pierre Fabre. Previously, his contributions and discoveries have led to the development and clinical evaluation of various antibodies at OncoMed Pharmaceuticals, as well as to the first clinical stage anti-HER3 antibody at U3 Pharma GmbH (acquired by Daiichi-Sankyo).

Edward studied chemistry at the Heinrich-Heine University, Düsseldorf and the Ludwig-Maximilian University of Munich, conducted his master’s thesis at the Max-Planck Institute of Neurobiology and received his Ph.D. in biochemistry from the Max-Planck Institute of Biochemistry in the lab of Prof. Axel Ullrich. Edward completed his postdoctoral training at Tularik, Inc (acquired by Amgen).

Thx 

Robert